Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer
January 17 2024 - 12:23PM
Business Wire
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS),
a clinical-stage biopharmaceutical company specializing in the
development of treatments for brain disorders, today announces the
reinforcement of its leadership team with the appointment of Arsène
Guekam as Chief Corporate Development Officer (CDO).
With over 15 years of experience in the Healthcare
(biotech/medtech) and financial sectors, Arsène Guekam brings an
unvaluable expertise to Aelis Farma in these fields. Graduate in
Pharmacy and from the EM Lyon's Programme Grandes Ecoles (finance
option), Arsène held key positions as a financial analyst in
several renowned brokers such as Oddo BHF, CM-CIC Securities, or
Crédit Lyonnais Small Caps. Before joining Aelis Farma, Arsène
served as Senior Analyst, Head of Biotech Research at Kepler
Cheuvreux, and later as Co-Head of Healthcare Research.
His extensive experience in financial markets and trend
analysis, combined with a profound understanding of the challenges
in the biotechnology industry, makes him an exceptional asset for
Aelis Farma.
As Chief Corporate Development Officer, Arsène will be
responsible for steering and overseeing the Company’s development
strategy, including identifying and evaluating new growth
opportunities, fostering strategic partnerships, and strengthening
relationships with investors.
Pier Vincenzo Piazza, CEO of Aelis Farma, states: "We are
delighted to welcome Arsène Guekam as Chief Corporate Development
Officer. This appointment aligns with our commitment to further
structure our leadership team to support our operational and
strategic development. His significant expertise and strategic
vision will be key assets in continuing and amplifying our
development in line with our roadmap and beyond, while increasing
Aelis' visibility within the entire financial community specialized
in this field."
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical
company that is developing a new class of drugs, the
Signaling-Specific inhibitors of the CB1 receptor of the
endocannabinoid system (CB1-SSi). CB1-SSi have been developed by
Aelis Farma based on the discovery of a natural regulatory
mechanism of CB1 hyperactivity made by the team led by Dr. Pier
Vincenzo Piazza, the Company’s CEO, when he was the director of the
Neurocentre Magendie of the INSERM in Bordeaux. By mimicking this
natural mechanism, CB1-SSi appear to selectively inhibit the
disease-related activity of the CB1 receptor without disrupting its
normal physiological activity. CB1-SSi have consequently the
potential to provide new safe treatments for several brain
diseases.
Aelis Farma is currently developing two first-in-class
clinical-stage drug candidates: AEF0117 for the treatment of
cannabis use disorder (CUD), currently being tested in a phase 2b
study in the United States; and AEF0217 for cognitive disorders,
including those of Down Syndrome (Trisomy 21), currently in a phase
1/2 study in Spain in people with Down syndrome. The Company also
has a portfolio of new innovative CB1-SSi for the treatment of
other disorders associated with a dysregulation of the activity of
the CB1 receptor.
Aelis Farma draws on the talents of more than 20 highly
qualified employees.
For more information, visit www.aelisfarma.com and follow us on
LinkedIn and Twitter.
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release are
forward-looking statements, not historical data. These
forward-looking statements are based on current beliefs,
expectations, and assumptions, including, but not limited to,
assumptions about Aelis Farma's current and future strategy and the
environment in which Aelis Farma operates. They involve known and
unknown risks, uncertainties, and other factors, which may cause
actual results, performance, or achievements, or industry results
or other events, to differ materially from those described or
implied by such forward-looking statements. These risks and
uncertainties include those set out and described in detail in
Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration
Document approved by the Autorité des Marchés Financiers on April
26, 2023, under number R.23-018.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions, or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117608527/en/
AELIS FARMA Pier Vincenzo Piazza CEO
contact@aelisfarma.com
NewCap Dusan Oresansky / Aurélie Manavarere Investor
Relations aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Media Relations aelis@newcap.fr +33
1 44 71 00 15
Aelis Farma (EU:AELIS)
Historical Stock Chart
From Apr 2024 to May 2024
Aelis Farma (EU:AELIS)
Historical Stock Chart
From May 2023 to May 2024